Business Wire

CIRIUM

3.1.2023 11:01:39 CET | Business Wire | Press release

Share
Most On-time Airlines and Airports of 2022 Unveiled by Cirium

Azul Airlines has been named as the global leader for airline on-time performance for 2022 by Cirium, the global aviation analytics leader. The Cirium 2022 On-Time Performance Review is the global gold standard for airline and airport performance and it will be published later this week, containing results for all airline categories, more detail and analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005047/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Passenger walks through an airport terminal on the way to catch a flight. Cirium, the aviation analytics company, has published its 2022 On-Time Performance rankings, looking at the top performing airlines and airports worldwide. The definitive, world-leading analysis recognises excellence in punctuality by the aviation industry globally. (Photo: Business Wire)

The past year saw a challenging operational environment across the world, particularly in Europe and North America, with many airlines and airports experiencing delays, disruptions and resource challenges. Others continue to emerge from Covid restrictions, especially in the Asia Pacific region. Despite this climate, many airlines and airports worldwide excelled.

For the second consecutive year Delta Air Lines was honored with the Cirium Platinum Award for global operational excellence. This award considers a number of factors including on-time performance, operational complexity and an airline’s ability to limit the impact of flight disruption to its passengers.

Alongside Delta’s Cirium Platinum Award, Azul was the global leader for on-time performance. The winners in the regions were Delta Air Lines in North America, Thai AirAsia for Asia Pacific, Oman Air for the Middle East and Africa, Azul in Latin America and Iberia in Europe. StarFlyer was the leading low-cost carrier and Haneda Airport was the top airport performer globally. More in-depth results are available below and will also appear at www.cirium.com, with the full report due to be published later this week.

An on-time flight is defined as a flight that arrives within 15 minutes of the scheduled gate arrival. For an airport it is defined as departing within 15 minutes of its scheduled departure.

Jeremy Bowen, Cirium CEO said: “Congratulations to Delta Air Lines for its excellent performance in Cirium’s 2022 On-Time Performance Review, getting its passengers to their destinations on time as the sector revived during 2022. Ramping back up operations so quickly after an enforced slowdown is not easy to do and the top-ranked airlines and airports in Cirium’s 2022 On-Time Performance Review deserve their recognition for this well-orchestrated achievement.”

During 2022 airlines had difficulty anticipating the sudden recovery in demand. They had been disappointed on several previous occasions throughout the pandemic, when it looked like demand was picking up, only for it to reverse course in the face of new Covid variants. When the recovery finally came this past year, the industry—including airlines, airports, air navigation providers and other stakeholders—struggled with understaffing and insufficient capacity. Delays and cancellations became issues. In time, however, operations greatly improved as the industry added workers and adjusted capacity. 2023 appears to hold great promise for the aviation industry.

Cirium looks forward to continuing to lead the way worldwide in monitoring aviation on-time performance in the New Year, as the industry adjusts to post-pandemic norms as they develop. The company’s data is designed to provide industry stakeholders with a neutral, third-party perspective, based on the widest and deepest pool of data collected and curated from more than 600 sources of real-time flight information. These include the airlines themselves, airports, global distribution systems, positional data, civil aviation authorities, air navigation service providers, proprietary data partnerships and the internet. Cirium’s on-time performance data is backed further by a completely independent board of advisors, comprised of industry experts with an unbiased view of the aviation sector. The board’s oversight ensures accuracy and proper representation of all the information the company presents.

Global airline leaders were:

Airline

On time ranking

On time arrival

Total flights

(AD) Azul

1

88.93%

279,722

(NH) ANA

2

88.61%

162,370

(JL) JAL

3

88.00%

165,981

(LA) LATAM Airlines

4

86.31%

451,651

(DL) Delta Air Lines

5

83.63%

1,004,684

(AV) SA AVIANCA

6

83.48%

144,525

(EK) Emirates

7

81.30%

137,589

(UA) United Airlines

8

80.46%

789,200

(QR) Qatar Airways

9

78.32%

152,377

(AA) American Airlines

10

78.29%

1,076,100

The top performing global airports of 2022 were:

Airport

On time ranking

On time departure

Total flights

(HND) Haneda Airport

1

90.33%

373,264

(BLR) Kempegowda International Airport

2

84.08%

201,897

(SLC) Salt Lake City International Airport

3

83.87%

226,545

(DTW) Detroit Metropolitan Wayne County Airport

4

82.62%

271,963

(PHL) Philadelphia International Airport

5

82.54%

233,777

(MSP) Minneapolis-St. Paul International Airport

6

81.95%

276,346

(DEL) Indira Gandhi International Airport

7

81.84%

411,205

(SEA) Seattle-Tacoma International Airport

8

81.04%

383,250

(BOG) El Dorado International Airport

9

80.72%

273,721

(CLT) Charlotte Douglas International Airport

10

80.68%

457,871

In North America the top ten airlines were:

Airline

On time ranking

On time arrival

Total flights

(DL) Delta Air Lines

1

83.63%

1,004,684

(UA) United Airlines

2

80.46%

789,200

(AS) Alaska Airlines

3

80.36%

243,072

(AA) American Airlines

4

78.29%

1,076,100

(WN) Southwest Airlines

5

74.06%

1,336,888

(F9) Frontier Airlines

6

68.32%

170,047

(B6) JetBlue Airways

7

66.35%

343,673

(G4) Allegiant Air

8

65.93%

117,469

(WS) WestJet

9

59.10%

94,663

(AC) Air Canada

10

54.51%

150,602

In Europe the leading airlines were:

Airline

On time ranking

On time arrival

Total flights

(IB) Iberia

1

85.87%

91,154

(UX) Air Europa

2

84.10%

48,163

(I2) Iberia Express

3

83.80%

35,665

(VY) Vueling

4

82.04%

197,546

(OS) Austrian

5

82.00%

95,708

(DY) Norwegian Air Shuttle

6

81.29%

71,561

(AZ) ITA Airways

7

80.29%

91,841

(D8) Norwegian Air International

8

79.03%

41,215

(AY) Finnair

9

75.16%

45,727

(LO) LOT - Polish Airlines

10

75.08%

85,902

In Latin America the results were:

Airline

On time ranking

On time arrival

Total flights

(AD) Azul

1

88.93%

279,722

(H2) Sky Airline

2

88.74%

27,161

(CM) Copa Airlines

3

88.02%

104,083

(LA) LATAM Airlines

4

86.31%

451,651

(AV) SA AVIANCA

5

83.48%

144,525

(AR) Aerolineas Argentinas

6

82.02%

94,982

(AM) Aeromexico

7

75.83%

113,814

(Y4) Volaris

8

71.61%

187,502

In Asia Pacific the leaders were:

Airline

On time ranking

On time arrival

Total flights

(FD) Thai AirAsia

1

91.56%

66,043

(NH) ANA

2

88.61%

162,370

(JL) JAL

3

88.00%

165,981

(HO) Juneyao Airlines

4

86.65%

88,115

(6E) IndiGo

5

84.11%

561,864

(I5) AirAsia India

6

83.70%

60,882

(NZ) Air New Zealand

7

81.29%

156,591

(MH) Malaysia Airlines

8

80.99%

95,962

(UK) Vistara

9

80.98%

87,901

(MM) Peach Aviation

10

79.81%

56,176

In the Middle East and Africa the most on-time airlines were:

Airline

On time ranking

On time arrival

Total flights

(WY) Oman Air

1

91.38%

29,631

(RJ) Royal Jordanian

2

86.76%

28,887

(KU) Kuwait Airways

3

81.64%

25,982

(EK) Emirates

4

81.30%

137,589

(QR) Qatar Airways

5

78.32%

152,377

(ET) Ethiopian Airlines

6

77.30%

102,571

(ME) Middle East Airlines

7

75.91%

20,654

(AT) Royal Air Maroc

8

72.01%

45,062

(LY) EL AL

9

69.80%

23,274

(SV) Saudia

10

69.75%

172,797

The leading low cost carriers were:

Airline

On time ranking

On time arrival

Total flights

(7G) StarFlyer

1

95.23%

21,894

(6J) Solaseed Air

2

94.53%

27,486

(FD) Thai AirAsia

3

91.56%

66,043

(AD) Azul

4

88.93%

279,722

(H2) Sky Airline

5

88.74%

27,161

(HD) Air Do

6

88.34%

22,187

(6E) IndiGo

7

84.11%

561,864

(I2) Iberia Express

8

83.80%

35,665

(I5) AirAsia India

9

83.70%

60,882

(VY) Vueling

10

82.04%

197,546

ENDS

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005047/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye